

Florian Scherer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2219967/publications.pdf>

Version: 2024-02-01

31
papers

6,126
citations

471509

17
h-index

526287

27
g-index

35
all docs

35
docs citations

35
times ranked

9744
citing authors

#	ARTICLE	IF	CITATIONS
1	Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer. <i>Molecular Oncology</i> , 2022, 16, 527-537.	4.6	42
2	T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10. <i>Nature Communications</i> , 2022, 13, 925.	12.8	104
3	Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis. <i>Cancers</i> , 2021, 13, 1151.	3.7	27
4	Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. <i>Nature Biotechnology</i> , 2021, 39, 1537-1547.	17.5	151
5	Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2605-2616.	1.6	37
6	Stringent Base Specific and Optimization-Free Multiplex Mediator Probe ddPCR for the Quantification of Point Mutations in Circulating Tumor DNA. <i>Cancers</i> , 2021, 13, 5742.	3.7	3
7	Tumor-Confirmed Follicular Lymphoma Mutations Are Detectable in Peripheral Blood Years Prior to Clinical Diagnosis. <i>Blood</i> , 2021, 138, 709-709.	1.4	1
8	Profiling of Circulating Tumor DNA for Noninvasive Disease Detection, Risk Stratification, and MRD Monitoring in Patients with CNS Lymphoma. <i>Blood</i> , 2021, 138, 6-6.	1.4	15
9	High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study. <i>Blood Advances</i> , 2020, 4, 3378-3381.	5.2	34
10	Personalized Treatment Selection and Disease Monitoring Using Circulating Tumor DNA Profiling in Real-World Cancer Patient Management. <i>Diagnostics</i> , 2020, 10, 550.	2.6	8
11	Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis. <i>British Journal of Haematology</i> , 2020, 190, e110-e114.	2.5	10
12	Capturing Tumor Heterogeneity and Clonal Evolution by Circulating Tumor DNA Profiling. <i>Recent Results in Cancer Research</i> , 2020, 215, 213-230.	1.8	15
13	Recurrent Crebbp Mutations in Follicular Lymphoma Appear Localized to the Committed B-Cell Lineage. <i>Blood</i> , 2020, 136, 30-31.	1.4	2
14	Change is Coming: Plan S From the Early Career Scientist Perspective. <i>HemaSphere</i> , 2020, 4, e500.	2.7	0
15	Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction. <i>Cell</i> , 2019, 178, 699-713.e19.	28.9	138
16	Age-Related Gliosis Promotes Central Nervous System Lymphoma through CCL19-Mediated Tumor Cell Retention. <i>Cancer Cell</i> , 2019, 36, 250-267.e9.	16.8	25
17	Determining cell type abundance and expression from bulk tissues with digital cytometry. <i>Nature Biotechnology</i> , 2019, 37, 773-782.	17.5	2,396
18	Reply to J. Wang et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 755-757.	1.6	2

#	ARTICLE	IF	CITATIONS
19	Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2018, 36, 2845-2853.	1.6	313
20	High-throughput sequencing for noninvasive disease detection in hematologic malignancies. Blood, 2017, 130, 440-452.	1.4	66
21	Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discovery, 2017, 7, 1394-1403.	9.4	701
22	Noninvasive Cancer Classification Using Diverse Genomic Features in Circulating Tumor DNA. , 2016, , .		0
23	Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Science Translational Medicine, 2016, 8, 364ra155.	12.4	348
24	Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nature Communications, 2016, 7, 11815.	12.8	520
25	Integrated digital error suppression for improved detection of circulating tumor DNA. Nature Biotechnology, 2016, 34, 547-555.	17.5	837
26	Isotype-switched follicular lymphoma displays dissociation between activation-induced cytidine deaminase expression and somatic hypermutation. Leukemia and Lymphoma, 2016, 57, 151-160.	1.3	16
27	Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 1089-1089.	1.4	8
28	Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood, 2015, 125, 3679-3687.	1.4	270
29	B-Cell Receptor Selection Pattern and Natural History Of Follicular Lymphoma. Blood, 2013, 122, 4258-4258.	1.4	0
30	Aid-Mediated Hypermutation of B-Cell Receptors with Subsequent Subclone Selection Define Biological Differences Between IgM-Expressing and Isotype-Switched Follicular Lymphoma. Blood, 2012, 120, 680-680.	1.4	0
31	Quantitative Analysis of AID Expression and Somatic Hypermutation Identifies Isotype-Switched and Non-Switched Follicular Lymphomas As Distinct Biological Subgroups,. Blood, 2011, 118, 3666-3666.	1.4	0